An officer of Vietnam’s National Institute of Hygiene and Epidemiology records the number of vaccines received – Photo: WHO Vietnam
The initial target of COVAX was 2 billion doses, but it will not be until the first quarter of 2022 that COVAX will reach this goal.
In a statement on September 8, COVAX said the decision to lower its vaccine supply target for the year to 1.425 billion doses was based on many factors, including the reason that India restricted vaccine exports.
Serum Institute of India – the vaccine manufacturer of AstraZeneca, is the main supplier of vaccines for COVAX. However, India was forced to limit vaccine exports in response to the domestic wave of the disease.
In addition, the production of vaccines by Johnson & Johnson has problems and the delay in applying for vaccine licenses from Novavax (USA) and Clover Biopharmaceuticals (China) also affects the supply of vaccines for vaccines. COVAX.
COVAX’s statement acknowledges: “Currently, COVAX’s ability to protect the world’s most vulnerable people continues to be impacted by export bans that favor bilateral agreements by manufacturers and countries, challenges continue to arise in the production expansion of some key manufacturers, and delays in applying for regulatory approval”.
Seth Berkley, executive director of GAVI – the Global Alliance for Vaccines and Immunization – told the media: “This situation is of course bad for the whole world as we see many dire consequences when it comes to vaccines. virus unchecked”.
Meanwhile, the World Health Organization (WHO) said low-income countries are ready to implement effective COVID-19 vaccination campaigns. It’s time for manufacturers and rich countries to fulfill their promise to deliver vaccines to reduce global health inequalities.
This is the time to “show real leadership, not empty promises,” declared WHO Director Tedros Adhanom Ghebreyesus.
The COVAX mechanism is co-directed by the World Health Organization (WHO), the Gavi Vaccine Alliance and the Coalition for Epidemic Preparedness Innovations (CEPI).
According to COVAX, only 20% of people in low- and middle-income countries receive the first injection, compared with 80% in rich countries. COVAX urges rich countries to share more vaccines.